Senti Biosciences, Inc. (SNTI)
(Delayed Data from NSDQ)
$0.35 USD
-0.01 (-3.65%)
Updated May 23, 2024 04:00 PM ET
Pre-Market: $0.33 -0.02 (-5.98%) 8:48 AM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
SNTI 0.35 -0.01(-3.65%)
Will SNTI be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SNTI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SNTI
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate
Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates
SNTI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
Other News for SNTI
Kronos Bio appoints Deborah Knobelman as COO, CFO
Senti Biosciences Announces Executive Leadership Restructuring
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
Senti Bio announces first patient dosed in Phase 1 trial of SENTI-202
Senti Biosciences GAAP EPS of -$0.26